How will labs adjust to an environment with multiple viruses hunting for human hosts?
In this webinar, our speakers will provide an introduction into the epidemiology of SARS-CoV-2, influenza A, and influenza B and explain why it is important to detect and differentiate all three viruses in a single test. We will introduce the workflow and performance of Thermo Fisher Scientific’s Emergency Use Authorized TaqPath COVID-19, Flu A, Flu B Combo Kit, a multiplex PCR test that can detect and differentiate between SARS-CoV-2, influenza A, and influenza B. The TaqPath COVID-19, Flu A, Flu B Combo Kit has a sample-to-results turnaround time of approximately 3 hours and supports testing of up to 94 samples in parallel.
- Explain the importance of simultaneous testing of SARS-CoV-2 and other respiratory viruses, especially during flu season
- Assess the approved workflow of an Emergency Use Authorized molecular diagnostic test for COVID-19 and influenza
- Evaluate performance data of the TaqPath COVID-19, Flu A, Flu B Combo Kit